

function. Again this is entirely consistent with the 2:1 efficacy ratio with no penalty paid in terms of side-effects. The recently published meta-analysis is again entirely consistent with this result. The results of the Donnelly *et al.* study may also have been influenced by the use of the budesonide MDI without a spacer. There is evidence from a number of sources that the budesonide MDI produces low lung delivery which may contribute to its lesser systemic side-effects. The addition of the final paragraph about anti-leukotriene drugs is odd. Leukotriene antagonists undoubtedly shows measurable clinical improvements in asthma control; however, the evidence from reports of active comparator studies is that inhaled steroids below doses which cause any peritubation of adrenocortical function are more effective.

NEIL BARNES, MD
Consultant Physician
London Chest Hospital,
Bonner Road,
London E2 9JX, U.K.

**Re: Asthma in the elderly:
underperceived, underdiagnosed, and
undertreated; a community survey**

The underdiagnosis of asthma in the elderly (1), even among life-long non-smokers, may partly be a consequence of the fact that the longer the duration of asthma (or the older the patient), the more likely the resemblance to chronic obstructive pulmonary disease (COPD), perhaps because of stigmata common to both diseases, such as small

airways involvement. The latter was documented in 12 out of 24 asthmatics of mean age 47 years, with symptoms of >5 years duration, in a recent pilot study (2). The undertreatment of asthmatics misclassified as having COPD can be remedied by implementing identical modules of stepped care for the two disorders (3), especially justifiable in view of the fact that the beneficial effects of inhaled corticosteroids on exercise capacity and frequency of severe relapses extend to patients with proven COPD, even when they are predominantly unresponsive to inhaled metered-dose beta-adrenergic stimulant bronchodilators (4).

O. M. P. JOLOBE
Department of Medicine for the Elderly
Tameside General Hospital,
Fountain Street,
Ashton-under-Lyme OL6 9RW, U.K.

References

1. Parameswaran K, Hildreth AJ, Chadha D, Keaney NP, Taylor IK, Bansal SK. Asthma in the elderly: underperceived, underdiagnosed and undertreated; a community survey. *Respir Med* 1998; **92**: 573–577.
2. Carr DH, Hibson S, Rubens M, Chung KF. Peripheral airways obstruction on high-resolution computed tomography in chronic severe asthma. *Respir Med* 1998; **92**: 448–453.
3. Jolobe OMP. Difficult treatment problems in respiratory disease (Letter). *Proc Roy Coll Phys Edinb* 1998; **28**: 125.
4. Paggiaro PL, Dahle R, Bakran L, *et al.* on behalf of the International COPD Study Group. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. *Lancet* 1988; **351**: 773–780.